Skip to content
PIL Logo

YERVOY 5 mg/ml concentrate for solution for infusion

Last Updated on eMC 16-Dec-2016 View changes  | Bristol-Myers Squibb Pharmaceutical Limited Contact details

Black Triangle icon This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Please click on the link to the left to view the PIL in PDF format.

Text only version for the visually impaired
Below is a text only representation of the Patient Information leaflet. The original may contain images or tables and can be viewed in PDF format using the link to the left. This PIL may be available from the RNIB in large print, Braille or audio CD. For further information please call the RNIB Medicine Leaflet line on 0800 198 5000. The product code(s) for this leaflet is/are: EU/1/11/698/001.



YERVOY 5 mg/ml concentrate for solution for infusion

Package leaflet: Information for the user

YERVOY 5 mg/ml concentrate for solution for infusion

ipilimumab

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What YERVOY is and what it is used for
2. What you need to know before you use YERVOY
3. How to use YERVOY
4. Possible side effects
5. How to store YERVOY
6. Contents of the pack and other information

1. What YERVOY is and what it is used for

YERVOY contains the active substance ipilimumab, a protein which helps your immune system to attack and destroy cancer cells by your immune cells.

Ipilimumab is used to treat advanced melanoma (a type of skin cancer) in adults.

2. What you need to know before you use YERVOY

You should not be given YERVOY

  • if you are allergic to ipilimumab or any of the other ingredients of this medicine (listed in Section 6 "Contents of the pack and other information"). Talk to your doctor if you are not sure.

Warnings and precautions

  • Talk to your doctor before using YERVOY.
    • inflammation of the intestines (colitis) which can worsen to bleedings or bowel perforation. Signs and symptoms of colitis may include diarrhoea (watery, loose or soft stools), an increased number of bowel movements than usual, blood in your stools or darker-coloured stools, pain or tenderness in your stomach area.
    • inflammation of the liver (hepatitis) that can lead to liver failure. Signs and symptoms of hepatitis may include eye or skin yellowing (jaundice), pain on the right side of your stomach area, tiredness.
    • inflammation of the skin that can lead to severe skin reaction (known as toxic epidermal necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)). Signs and symptoms of severe skin reaction may include such as skin rash with or without itching, peeling of the skin, dry skin, fever, fatigue, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells) and effects on liver, kidneys or lungs. Please note that the reaction called DRESS may develop weeks or months after your last dose.
    • inflammation of the nerves that can lead to paralysis. Symptoms of nerve problems may include muscle weakness, numbness or tingling in your hands or feet, loss of consciousness or difficulty waking up.
    • inflammation of hormone producing glands (especially the pituitary, adrenal and thyroid glands) that may affect how these glands work. Signs and symptoms that your glands are not working properly may include headaches, blurry or double vision, tiredness, decreased sexual drive, behavioral changes.
    • inflammation of the eyes. Signs and symptoms may include redness in the eye, pain in the eye, vision problems or blurry vision.

Tell your doctor immediately if you have any of these signs or symptoms or they get worse. Do not try to treat your symptoms with other medicines. Your doctor may give you other medicines in order to prevent more severe complications and reduce your symptoms, withhold the next dose of YERVOY, or stop your treatment with YERVOY altogether.

Please note that these signs and symptoms are sometimes delayed, and may develop weeks or months after your last dose. Before treatment, your doctor will check your general health. You will also have blood tests during treatment.

Check with your doctor or nurse before you are given YERVOY

  • if you have an autoimmune disease (a condition where the body attacks its own cells);
  • if you have, or have ever had, chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV);
  • if you have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS).
  • if you have previously experienced a severe skin adverse reaction on a prior cancer therapy.

Children and adolescents

YERVOY should not be used in children and adolescents below 18 years of age until more information becomes available.

Other medicines and YERVOY

Before you are given YERVOY, tell your doctor

  • if you are taking any medicines that suppress your immune system, such as corticosteroids. These medicines may interfere with the effect of YERVOY. However, once you are treated with YERVOY, your doctor may give you corticosteroids to reduce the side-effects that you may have with YERVOY.
  • if you are taking any medicines that stop your blood from clotting (anticoagulants). These medicines may increase the likelihood of bleeding in the stomach or intestine, which is a side-effect of YERVOY.

Also tell your doctor if you are taking or have recently taken any other medicines.

Do not take any other medicines during your treatment without talking to your doctor first. Based on early data, the combination of YERVOY (ipilimumab) and Zelboraf (vemurafenib, another medicine for the treatment of melanoma) is not recommended due to increased toxicity to the liver.

Pregnancy and breast-feeding

Tell your doctor if you are pregnant, if you are planning to become pregnant, or if you are breast-feeding.

You must not use YERVOY if you are pregnant unless your doctor specifically recommends it. The effects of YERVOY in pregnant women are not known, but it is possible that the active substance, ipilimumab, could harm an unborn baby.

  • You must use effective contraception while you are being treated with YERVOY if you are a woman who could become pregnant.
  • If you become pregnant while using YERVOY tell your doctor.

It is not known whether ipilimumab gets into breast milk. However, significant exposure of ipilimumab to the infant through breast milk is not expected and no effects on the breast-fed infant are anticipated. Ask your doctor if you can breast-feed during or after treatment with YERVOY.

Driving and using machines

Do not drive or use machines after you have been given YERVOY unless you are sure you are feeling well. Feeling tired or weak is a very common side effect of YERVOY. This can affect your ability to drive or to use machines.

YERVOY contains sodium

Tell your doctor if you are on a low-sodium (low-salt) diet before you are given YERVOY. It contains 2.3 mg sodium per ml of concentrate.

3. How to use YERVOY

How YERVOY is given

YERVOY will be given to you in a hospital or clinic under the supervision of an experienced doctor.

It will be given to you as an infusion (a drip) into a vein (intravenously) over a period of 90 minutes.

How much YERVOY is given

The recommended dose is 3 mg of ipilimumab per kilogram of your body weight.

The amount of YERVOY you will be given will be calculated based on your body weight. Depending on your dose, some or all of the content of the YERVOY vial may be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection or 50 mg/ml (5%) glucose solution for injection before use. More than one vial may be necessary to obtain the required dose.

You will be treated with YERVOY once every 3 weeks, for a total of 4 doses. You may notice the appearance of new lesions or growth of existing lesions on your skin, which can be expected when you are being treated with YERVOY. Your doctor will continue giving you YERVOY for a total of 4 doses, depending on your tolerance to the treatment.

If you miss a dose of YERVOY

It is very important for you to keep all your appointments to receive YERVOY. If you miss an appointment, ask your doctor when to schedule your next dose.

If you stop using YERVOY

Stopping your treatment may stop the effect of the medicine. Do not stop treatment with YERVOY unless you have discussed this with your doctor.

If you have any further questions about your treatment or the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the risks and benefits of your treatment.

Be aware of important symptoms of inflammation

YERVOY acts on your immune system and may cause inflammation in parts of your body.

Inflammation may cause serious damage to your body and some inflammatory conditions may be life-threatening.

The following side effects have been reported in clinical trials in patients receiving 3 mg/kg ipilimumab:

Very common (may affect more than 1 in 10 people)

  • loss of appetite
  • diarrhoea, vomiting or feeling sick (nausea)
  • skin rash, itching
  • feeling tired or weak, reaction at site of injection, fever
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

Common (may affect up to 1 in 10 people)

  • tumour pain
  • underactive function of the thyroid gland which can cause tiredness or weight gain, underactive function of the pituitary gland
  • dehydration
  • confusion
  • damage to the nerves (causing pain, weakness and cramps), dizziness, headache,
  • blurred vision, pain in the eye
  • low blood pressure, temporary redness of the face and neck, feeling of intense heat with sweating and rapid heart beat
  • shortness of breath, cough
  • bleeding in the stomach or intestine, inflammation of the intestines (colitis), constipation, heartburn, stomach pain
  • abnormal function of the liver
  • inflammation of the inner surface lining of a particular organ
  • inflammation and redness of the skin, skin colour change in patches (vitiligo), hives (itchy, bumpy rash), hair loss or thinning, excessive sweating at night, dry skin
  • pain in muscles and joints, muscle spasms
  • shivering, lack of energy, swelling, pain
  • flu-like illness
  • weight loss
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

Uncommon (may affect up to 1 in 100 people)

  • serious bacterial infection of the blood (sepsis, septic shock), inflammation around the brain or spinal cord, inflammation of the stomach and intestines, inflammation of bowel wall (causing fever, vomiting and stomach pain), urinary tract infection, infection of the respiratory tract
  • a group of symptoms due to cancer in the body such as high blood levels of calcium and cholesterol, and low blood levels of sugar (paraneoplastic syndrome)
  • allergic reaction
  • underactive function of the adrenal glands, overactive function of the thyroid gland, which can cause rapid heart rate, sweating and weight loss, defect of the glands producing sex hormones
  • decreased function of the adrenal glands caused by an underactive hypothalamus (part of the brain)
  • a group of metabolic complications occurring after cancer treatment characterised by high blood levels of potassium and phosphate, and low blood levels of calcium (tumour lysis syndrome).
  • changes in mental health, depression, lowered sex drive
  • severe and possibly fatal inflammation of the nerves causing pain, weakness or paralysis in the extremities (Guillain-Barré syndrome), fainting, inflammation of the nerves within the brain, excessive accumulation of fluid in the brain,difficulty in coordinating movements (ataxia), shaking, brief involuntary muscle contraction, difficulty in speaking
  • inflammation of the eye which causes redness or pain, bleeding in the eye, inflammation of the coloured part of the eye, reduced vision, a foreign body sensation in the eyes, swollen runny eyes, swelling of the eye, inflammation of the eyelids
  • irregular or abnormal heart beat
  • inflammation of the blood vessels, disease of the blood vessels, restriction in the blood supply to the extremities, low blood pressure when standing up
  • extreme difficulty in breathing, fluid accumulation in the lungs, inflammation of the lungs, hay fever
  • bowel perforation, inflammation of the membrane of the stomach wall, inflammation of the small intestine, inflammation of the bowel or the pancreas, peptic ulcer, inflammation of the food pipe, blockage of the intestines
  • liver failure, inflammation of the liver, enlarged liver, yellowing of the skin or eyes (jaundice)
  • severe and possibly fatal peeling of the skin (toxic epidermal necrolysis)
  • inflammation of the muscles causing pain or stiffness in the hip and shoulder, painful joints
  • inflammation of the thyroid gland, the kidney, or the central nervous system
  • multi organ inflammation
  • inflammation of skeletal muscles
  • muscle weakness
  • kidney function failure, kidney disease
  • absence of menstrual periods
  • multi organ dysfunction, reaction related to infusion of the medicine
  • change in hair colour
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

Rare (may affect up to 1 in 1,000 people)

  • inflammatory disease of blood vessels (most commonly head arteries)
  • inflammation of the anus and the rectal wall (marked by bloody stools and a frequent urge to defecate)
  • skin disease characterized by dry red patches covered with scales (psoriasis)
  • inflammation and redness of the skin (erythema multiforme)
  • a type of severe skin reaction characterized by rash accompanied by one or more of the following features: fever, swelling of the face or lymph glands, increase of eosinophils (type of white blood cells), effects on liver, kidneys or lungs (a reaction called DRESS).
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

Very rare (may affect up to 1 in 10,000 people)

  • Serious, potential life-threatening allergic reaction
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

In addition, the following uncommon (may affect up to 1 in 100 people) side effects have been reported in patients who received doses other than 3mg/kg of YERVOY in clinical trials:

  • triad of symptoms (meningism): neck stiffness, intolerance of bright light and headache, flu-like discomfort
  • inflammation of the heart muscle, weakness of the heart muscle, fluid around the heart
  • inflammation of the liver or the pancreas, nodules of inflammatory cells in various organs of your body
  • infection within the abdomen
  • painful skin lesions of the arms and legs and face (erythema nodosum)
  • overactive pituitary gland
  • decreased function of the parathyroid gland
  • inflammation of the eye, eye muscle inflammation
  • decreased hearing
  • poor blood circulation which makes toes and fingers numb or pale
  • damage to the tissues of the hands and feet resulting in redness, swelling and blisters
  • Tell your doctor immediately if you get any of these side effects.
    Do not try to treat your symptoms with other medicines.

Changes in test results

YERVOY may cause changes in the results of tests carried out by your doctor. These include:

  • a variation in the number of red blood cells (which carry oxygen), white blood cells (which are important in fighting infection) or platelets (cells which help the blood to clot)
  • an abnormal variation of hormones and liver enzyme levels in the blood
  • abnormal liver function test
  • abnormal levels of calcium, sodium, phosphate or potassium in the blood
  • presence of blood or proteins in the urine
  • an abnormally high alkalinity of the blood and other body tissues
  • kidneys unable to remove acids from blood normally
  • presence of antibodies in the blood against some of your own cells

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.

Ireland

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
e-mail: medsafety@hpra.ie

Malta

ADR Reporting
Website: www.medicinesauthority.gov.mt/adrportal

United Kingdom

Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard

5. How to store YERVOY

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C to 8°C).

Do not freeze.

Store in the original package in order to protect from light.

Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.

6. Contents of the pack and other information

What YERVOY contains

  • The active substance is ipilimumab.
    Each ml of concentrate contains 5 mg of ipilimumab.
    Each 10 ml vial contains 50 mg of ipilimumab.
    Each 40 ml vial contains 200 mg of ipilimumab.
  • The other ingredients are Tris-hydrochloride, sodium chloride (see section 2 "YERVOY contains sodium"), mannitol (E421), pentetic acid, polysorbate 80, sodium hydroxide, hydrochloric acid and water for injections.

What YERVOY looks like and contents of the pack

YERVOY concentrate for solution for infusion is clear to slightly opalescent, colourless to pale yellow and may contain light (few) particulates.

It is available in packs containing either 1 glass vial of 10 ml or 1 glass vial of 40 ml.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Bristol-Myers Squibb Pharma EEIG
Uxbridge Business Park
Sanderson Road
Uxbridge
UB8 1DH
United Kingdom

Manufacturer

Bristol-Myers Squibb S.r.l.
Contrada Fontana del Ceraso
03012 Anagni (FR)
Italy

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Bristol-Myers Squibb Pharmaceuticals Ltd
Tel: + 44 (0800) 731 1736

This leaflet was last revised in November 2016

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu

Certain risk materials on this website are intended for use by healthcare professionals only.

By proceeding you are confirming that you are a healthcare professional.

Want to avoid this message? If you are a Healthcare professional, REGISTER or LOGIN and you will not have to self-certify when you access Risk Minimisation Materials.

You can leave feedback on specific Risk Minimisation Materials or make general observations about how they are displayed on the eMC by leaving comments in the box below.

Please note that we are unable to respond to medical queries.

YERVOY 5 mg/ml concentrate for solution for infusion


Please enter your email address below

Tick here if you wish to recieve a response to your feedback

Risk Materials
VIEW

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Yervoy (ipilimumab) Healthcare Professional Frequently Asked Questions Brochure

This risk minimisation material is a condition of the marketing authorisation.

If you would like a hard copy of the Yervoy (ipilimumab) risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 731 1736; e-mail: medical.information@bms.com) with your specific request.

For Healthcare Professionals

Yervoy (ipilimumab) Patient Alert Card - Printable Version

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

Yervoy (ipilimumab) Patient Alert Card – Read Only Version

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information that you need to be aware of before you are given Yervoy (ipilimumab) and during treatment with Yervoy (ipilimumab).

Yervoy (ipilimumab) Patient Information Brochure

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material as it contains important safety information.

CLOSE THIS PANEL

Company contact details

Bristol-Myers Squibb Pharmaceutical Limited

Company image
Address

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH, UK

Medical Information Direct Line

+44 (0) 800 731 1736

Telephone

+44 (0)1895 523 000

Medical Information e-mail

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ipilimumab

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue